{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T03:21:38Z","timestamp":1761016898423,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological and Toxicological Methods"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.vascn.2011.06.002","type":"journal-article","created":{"date-parts":[[2011,7,5]],"date-time":"2011-07-05T18:23:53Z","timestamp":1309890233000},"page":"158-163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Automated blood sampling to identify pharmacodynamics biomarkers of corticotrophin releasing factor receptor 1 antagonism"],"prefix":"10.1016","volume":"64","author":[{"given":"S.D.","family":"Katugampola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Fish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Da Costa Mathews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vascn.2011.06.002_bb0005","doi-asserted-by":"crossref","first-page":"6068","DOI":"10.1128\/IAI.70.11.6068-6074.2002","article-title":"Corticotropin-releasing hormone augments proinflammatory cytokine production from macrophages in vitro and in lipopolysaccharide-induced endotoxin shock in mice","volume":"70","author":"Agelaki","year":"2002","journal-title":"Infection and Immunity"},{"key":"10.1016\/j.vascn.2011.06.002_bb0170","doi-asserted-by":"crossref","unstructured":"Brignol, N., McMahon, L. M., Luo, S., & Tse, F. L. (2001). High-throughput semi-automated 96-well liquid\/liquid extraction and liquid chromatography\/mass spectrometric analysis of everolimus (RAD 001) and cyclosporin a (CsA) in whole blood. Rapid Communications in Mass Spectrometry, 15(12), 898\u2013907.","DOI":"10.1002\/rcm.323"},{"key":"10.1016\/j.vascn.2011.06.002_bb0010","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/0165-6147(96)81594-X","article-title":"Corticotrophin-releasing factor receptors: From molecular biology to drug design","volume":"17","author":"Chalmers","year":"1996","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.vascn.2011.06.002_bb0015","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 percent inhibition (IC50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.vascn.2011.06.002_bb0020","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3109\/07435808509035423","article-title":"Effect of naloxone on the hormone response to CRF in normal man","volume":"11","author":"Conaglen","year":"1985","journal-title":"Endocrine Research"},{"key":"10.1016\/j.vascn.2011.06.002_bb0025","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1523\/JNEUROSCI.07-01-00088.1987","article-title":"Corticotropin-releasing factor receptors in the rat central nervous system: Characterization and regional distribution","volume":"7","author":"De Souza","year":"1987","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.vascn.2011.06.002_bb0030","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/0306-4530(95)00011-9","article-title":"Corticotropin-releasing factor receptors: Physiology, pharmacology, biochemistry and role in central nervous system and immune disorders","volume":"20","author":"De Souza","year":"1995","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.vascn.2011.06.002_bb0035","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrd1130","article-title":"Clinical biomarkers in drug discovery and development","volume":"2","author":"Frank","year":"2003","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.vascn.2011.06.002_bb0040","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0968-0896(99)00271-0","article-title":"The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine: A corticotropin-releasing factor (hCRF1) antagonist","volume":"8","author":"Gilligan","year":"2000","journal-title":"Bioorganic & Medicinal Chemistry"},{"key":"10.1016\/j.vascn.2011.06.002_bb0045","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.pharmthera.2009.03.002","article-title":"Target site occupancy: Emerging generalizations from clinical and preclinical studies","volume":"122","author":"Grimwood","year":"2009","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.vascn.2011.06.002_bb0050","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0893-133X(02)00299-3","article-title":"Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist","volume":"27","author":"Heinrichs","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.vascn.2011.06.002_bb0055","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/j.1365-2265.1984.tb01399.x","article-title":"Differential effects of ovine and human corticotrophin-releasing factor in human subjects","volume":"21","author":"Hermus","year":"1984","journal-title":"Clinical Endocrinology"},{"key":"10.1016\/j.vascn.2011.06.002_bb0060","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.ejphar.2007.12.032","article-title":"Central CRH system in depression and anxiety\u2013evidence from clinical studies with CRH1 receptor antagonists","volume":"583","author":"Holsboer","year":"2008","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.vascn.2011.06.002_bb0065","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1037\/1064-1297.15.6.519","article-title":"CRH-sub-1 receptor antagonists for the treatment of depression and anxiety","volume":"15","author":"Ising","year":"2007","journal-title":"Experimental and Clinical Psychopharmacology"},{"key":"10.1016\/j.vascn.2011.06.002_bb0070","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1021\/jm034077k","article-title":"Autoradiographic visualization of corticotropin releasing hormone type 1 receptors with a nonpeptide ligand: synthesis of [(76)Br]MJL-1-109-2","volume":"46","author":"Jagoda","year":"2003","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.vascn.2011.06.002_bb0075","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1152\/jn.01148.2007","article-title":"Pro- and anti-nociceptive effects of corticotropin-releasing factor (CRF) in central amygdala neurons are mediated through different receptors","volume":"99","author":"Ji","year":"2008","journal-title":"Journal of Neurophysiology"},{"key":"10.1016\/j.vascn.2011.06.002_bb0085","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1016\/j.bmc.2006.02.019","article-title":"Synthesis and in vivo evaluation of [11C]SN003 as a PET ligand for CRF1 receptors","volume":"14","author":"Kumar","year":"2006","journal-title":"Bioorganic & Medicinal Chemistry"},{"key":"10.1016\/j.vascn.2011.06.002_bb0090","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1124\/jpet.103.058784","volume":"309","author":"Lelas","year":"2004","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.vascn.2011.06.002_bb0095","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1527-3458.2005.tb00034.x","article-title":"The pharmacology of DMP696 and DMP904, non peptidergic CRF1 receptor antagonist","volume":"11","author":"Li","year":"2005","journal-title":"CNS Drug Reviews"},{"key":"10.1016\/j.vascn.2011.06.002_bb0105","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0969-8051(00)00199-2","article-title":"Synthesis and characterization of fluorinated and iodinated pyrrolopyrimidines as PET\/SPECT ligands for the CRF1 receptor","volume":"28","author":"Martarello","year":"2001","journal-title":"Nuclear Medicine and Biology"},{"key":"10.1016\/j.vascn.2011.06.002_bb0110","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/(SICI)1096-9861(19990607)408:3<365::AID-CNE5>3.0.CO;2-N","article-title":"Autoradiographic and in situ hybridization localization of corticotropin-releasing factor 1 and 2 receptors in nonhuman primate brain","volume":"408","author":"S\u00e1nchez","year":"1999","journal-title":"The Journal of Comparative Neurology"},{"key":"10.1016\/j.vascn.2011.06.002_bb0115","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1210\/jcem-59-6-1103","article-title":"Human corticotropin-releasing factor in man: Pharmacokinetic properties and dose-response of plasma adrenocorticotropin and cortisol secretion","volume":"59","author":"Sch\u00fcrmeyer","year":"1984","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.vascn.2011.06.002_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000124240","article-title":"Intravenous application of ovine and human corticotropin releasing factor (CRF): ACTH, cortisol and CRF levels","volume":"42","author":"Stalla","year":"1986","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.vascn.2011.06.002_bb0125","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.nucmedbio.2007.01.012","article-title":"PET Imaging of CRF1 with [11C]R121920 and [11C]DMP696: Is the target of sufficient density?","volume":"34","author":"Sullivan","year":"2007","journal-title":"Nuclear Medicine and Biology"},{"key":"10.1016\/j.vascn.2011.06.002_bb0130","doi-asserted-by":"crossref","first-page":"G173","DOI":"10.1152\/ajpgi.2001.280.2.G173","article-title":"Stress and the gastrointestinal tract III. Stress-related alterations of gut motor function: Role of brain corticotropin-releasing factor receptors","volume":"280","author":"Tach\u00e9","year":"2001","journal-title":"American Journal of Physiology. Gastrointestinal and Liver Physiology"},{"key":"10.1016\/j.vascn.2011.06.002_bb0135","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/520","article-title":"Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1","volume":"19","author":"Timpl","year":"1998","journal-title":"Nature Genetics"},{"key":"10.1016\/j.vascn.2011.06.002_bb0140","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1126\/science.6267699","article-title":"Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin","volume":"213","author":"Vale","year":"1981","journal-title":"Science"},{"key":"10.1016\/j.vascn.2011.06.002_bb0145","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1146\/annurev.pharmtox.48.113006.094611","article-title":"Strategic approach to fit-for-purpose biomarkers in drug development","volume":"48","author":"Wagner","year":"2008","journal-title":"Annual Review of Pharmacology and Toxicology"},{"key":"10.1016\/j.vascn.2011.06.002_bb0155","doi-asserted-by":"crossref","first-page":"R1671","DOI":"10.1152\/ajpregu.91013.2008","article-title":"Social stress-induced bladder dysfunction: Potential role of corticotropin-releasing factor","volume":"296","author":"Wood","year":"2009","journal-title":"American Journal of Physiology. Regulatory, Integrative and Comparative Physiology"},{"key":"10.1016\/j.vascn.2011.06.002_bb0160","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0022-3956(00)00016-9","article-title":"Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: The first 20 patients treated","volume":"34","author":"Zobel","year":"2000","journal-title":"Journal of Psychiatric Research"},{"key":"10.1016\/j.vascn.2011.06.002_bb0165","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0006-8993(02)03189-X","article-title":"Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat","volume":"952","author":"Zorrilla","year":"2002","journal-title":"Brain Research"}],"container-title":["Journal of Pharmacological and Toxicological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105687191100253X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105687191100253X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T23:56:18Z","timestamp":1761004578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S105687191100253X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S105687191100253X"],"URL":"https:\/\/doi.org\/10.1016\/j.vascn.2011.06.002","relation":{},"ISSN":["1056-8719"],"issn-type":[{"type":"print","value":"1056-8719"}],"subject":[],"published":{"date-parts":[[2011,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Automated blood sampling to identify pharmacodynamics biomarkers of corticotrophin releasing factor receptor 1 antagonism","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological and Toxicological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vascn.2011.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}